| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $37,287,840 | 22 | 100 |
| Gregg Vicky B | director | 0 | $0 | 1 | $239,700 | $-239,700 |
| PFEIFFER GARY M | director | 0 | $0 | 1 | $292,329 | $-292,329 |
| DELANEY MARK E | SVP & Chief Commercial Officer | 0 | $0 | 2 | $1.86M | $-1.86M |
| Plewman Patrick | SVP for Diagnostic Services | 0 | $0 | 4 | $2.03M | $-2.03M |
| KUPPUSAMY KARTHIK | SVP, Clinical Solutions | 0 | $0 | 2 | $2.17M | $-2.17M |
| PREVOZNIK MICHAEL E | SVP & General Counsel | 0 | $0 | 4 | $6.65M | $-6.65M |
| Doherty Catherine T. | EVP, Regional Businesses | 0 | $0 | 4 | $6.96M | $-6.96M |
| Davis J. E. | CEO and President | 0 | $0 | 4 | $17.08M | $-17.08M |
Quest Diagnostics Incorporated, founded in 1967 and headquartered in Secaucus, New Jersey, is a premier provider of diagnostic testing, information, and related services, serving clients both domestically and internationally. Its core business involves the development and provision of diverse diagnostic information services, such as routine, advanced clinical, and anatomic pathology testing. While primarily operating under the Quest Diagnostics brand, it also leverages specialized identities like AmeriPath, Dermpath Diagnostics, ExamOne, and …
Over the last 12 months, insiders at Quest Diagnostics Incorporated have bought $0 and sold $37.29M worth of Quest Diagnostics Incorporated stock.
On average, over the past 5 years, insiders at Quest Diagnostics Incorporated have bought $0 and sold $21.26M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 8,000 shares for transaction amount of $444,046 was made by GUINAN MARK (Senior Vice President & CFO) on 2014‑05‑05.
| 2026-10-26 | Sale | PFEIFFER GARY M | director | 1,203 0.0011% | $243.00 | $292,329 | +2.46% | |
| 2026-09-01 | Sale | Davis J. E. | CEO and President | 10,000 0.0093% | $242.72 | $2.43M | +0.19% | |
| 2026-08-28 | Sale | PREVOZNIK MICHAEL E | SVP & General Counsel | 22,677 0.0206% | $243.11 | $5.51M | -2.51% | |
| 2026-07-28 | Sale | DELANEY MARK E | SVP & Chief Commercial Officer | 1,600 0.0014% | $235.18 | $376,288 | +0.51% | |
| 2026-06-04 | Sale | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | 8,147 0.0075% | $200.00 | $1.63M | +19.95% | |
| 2026-06-01 | Sale | Davis J. E. | CEO and President | 10,000 0.0091% | $194.14 | $1.94M | +22.02% | |
| 2026-03-05 | Sale | Doherty Catherine T. | EVP, Regional Businesses | 5,558 0.0051% | $206.21 | $1.15M | +2.90% | |
| 2026-03-05 | Sale | PREVOZNIK MICHAEL E | SVP & General Counsel | 3,878 0.0035% | $206.21 | $799,682 | +2.90% | |
| 2026-03-05 | Sale | Plewman Patrick | SVP for Diagnostic Services | 2,855 0.0026% | $206.21 | $588,730 | +2.90% | |
| 2026-03-04 | Sale | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | 2,628 0.0023% | $204.86 | $538,372 | +0.65% | |
| 2026-03-03 | Sale | Doherty Catherine T. | EVP, Regional Businesses | 632 0.0006% | $207.73 | $131,285 | +0.60% | |
| 2026-03-03 | Sale | PREVOZNIK MICHAEL E | SVP & General Counsel | 526 0.0005% | $207.73 | $109,266 | +0.60% | |
| 2026-03-03 | Sale | Plewman Patrick | SVP for Diagnostic Services | 410 0.0004% | $207.73 | $85,169 | +0.60% | |
| 2026-03-02 | Sale | Davis J. E. | CEO and President | 10,000 0.009% | $212.52 | $2.13M | -0.40% | |
| 2026-02-19 | Sale | Doherty Catherine T. | EVP, Regional Businesses | 1,433 0.0013% | $204.83 | $293,521 | +3.48% | |
| 2026-02-19 | Sale | PREVOZNIK MICHAEL E | SVP & General Counsel | 1,111 0.001% | $204.83 | $227,566 | +3.48% | |
| 2026-02-19 | Sale | Plewman Patrick | SVP for Diagnostic Services | 958 0.0009% | $204.83 | $196,227 | +3.48% | |
| 2026-02-13 | Sale | Doherty Catherine T. | EVP, Regional Businesses | 26,165 0.0234% | $206.15 | $5.39M | +1.12% | |
| 2026-02-10 | Sale | Plewman Patrick | SVP for Diagnostic Services | 5,662 0.005% | $204.00 | $1.16M | +1.85% | |
| 2025-11-25 | Sale | Davis J. E. | CEO and President | 55,093 0.0495% | $192.22 | $10.59M | +5.46% |
| RUSCKOWSKI STEPHEN H | Chairman, CEO and President | 334833 0.3034% | $82.72M | 2 | 16 | +0.93% |
| GUINAN MARK | Executive Vice President & CFO | 73579 0.0667% | $18.18M | 1 | 5 | +14.91% |
| STANZIONE DANIEL | director | 28349 0.0257% | $7M | 1 | 9 | +6.39% |
| BONGIORNO THOMAS F | VP and Corporate Controller | 12477 0.0113% | $3.08M | 1 | 24 | +3.61% |
| MAIN TIMOTHY L | director | 5658 0.0051% | $1.4M | 1 | 0 | +20.27% |
| FLAHERTY JAMES F III | director | 0 0% | $0 | 3 | 1 | +20.39% |
| Increased Positions | 506 | +45.63% | 8M | +7.64% |
| Decreased Positions | 451 | -40.67% | 11M | -9.98% |
| New Positions | 143 | New | 2M | New |
| Sold Out Positions | 96 | Sold Out | 864,382 | Sold Out |
| Total Postitions | 1,164 | +4.96% | 107M | -2.34% |
| Vanguard Group Inc | $2.48M | 12.84% | 14.25M | +18,056 | +0.13% | 2025-09-30 |
| Blackrock, Inc. | $1.74M | 9.01% | 10M | -310,940 | -3.02% | 2025-09-30 |
| Price T Rowe Associates Inc /Md/ | $1.22M | 6.31% | 7.01M | -188,707 | -2.62% | 2025-09-30 |
| State Street Corp | $907,867.00 | 4.71% | 5.22M | +38,931 | +0.75% | 2025-09-30 |
| Jpmorgan Chase & Co | $750,319.00 | 3.89% | 4.32M | -14,269 | -0.33% | 2025-09-30 |
| Boston Partners | $701,570.00 | 3.64% | 4.04M | +997,033 | +32.8% | 2025-09-30 |
| Geode Capital Management, Llc | $527,711.00 | 2.74% | 3.04M | +54,070 | +1.81% | 2025-09-30 |
| Victory Capital Management Inc | $407,359.00 | 2.11% | 2.34M | -465,252 | -16.56% | 2025-09-30 |
| Morgan Stanley | $397,442.00 | 2.06% | 2.29M | +141,806 | +6.61% | 2025-09-30 |
| Dimensional Fund Advisors Lp | $331,506.00 | 1.72% | 1.91M | +6,155 | +0.32% | 2025-09-30 |